Dear EBMT friends and colleagues,
This represents my first President’s message for EBMT and I am very proud and excited that I have this opportunity to work with you and I am extremely grateful for the trust you have placed in me. I want to extend special thanks to the Executive Board, the Board of Association and in particular Mohamad Mohty who masterfully directed our society as President in the last four years into the secure globally significant and relevant society it is today.
As you will read in this Bulletin, our Annual Meeting in Lisbon was a major success and the Local Organizing Committee under the leadership of Manuel Abecasis deserves special thanks for their hard work which resulted in a record attendance of 5,261 delegates and 1,213 submitted abstracts. The diverse and exciting program covered beside stem cell transplantation other immunological and cell based therapies, such as bispecific antibodies, checkpoint inhibitors, genetically modified T–cells including CAR-T Cells and Genome-edited hematopoietic stem cells. This compelling programme reflected the growing leadership role of our society in the field of cellular therapies. These compellingly important new therapies offer an additional route to achieve our mission of saving more lives of our patients with blood cancer or life threatening diseases and their effective development is clearly a major opportunity and challenge for EBMT.
With your help, the support of the Board of Association and of the Scientific Council as well as the tireless staff in the EBMT offices we will further strengthen our scientific and educational activities and efforts in patient advocacy as one of the leading society in stem cell transplantation and cellular therapies worldwide.
I am greatly looking forward to working with you all in the coming years as we strive to improve treatment options and outcomes for our patients.